https://www.selleckchem.com/pr....oducts/ag-221-enasid
With all available strategies, virtually no patient who needs an allogeneic transplant should be excluded by the absence of a donor. The recent advances in the field of haplo-HSCT have allowed a large number of patients with incurable diseases to benefit from this procedure despite not having a matched donor. With all available strategies, virtually no patient who needs an allogeneic transplant should be excluded by the absence of a donor. The authors report a38-year-old woman with primary Sjögren's syndrome who initially show
Like
Comment
Share
